A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.
The safety, infectivity, immunogenicity, and phenotypic stability of the cold-passaged (cp) candidate vaccine cp-45, a cold-adapted (ca), temperature-sensitive (ts) mutant of the JS strain of human parainfluenza virus type 3 (HPIV-3), was evaluated in 114 children 6 months to 10 years old in a randomized, placebo-controlled, double-blind trial.
The cp-45 vaccine was well tolerated when given intranasally to parainfluenza virus type 3 (PIV-3) - seropositive and - seronegative children.
With 104 or 105 TCID50 of cp-45 vaccine, 86% of seronegative vaccinees were infected, 83% of whom shed virus at a mean peak titer of 102.2 pfu/mL.
Virus present in respiratory specimens retained the ts phenotype, and each of 86 PIV-3 isolates tested retained both the ca and ts phenotypes.
One dose of 105 TCID50 of vaccine induced a serum hemagglutination-inhibiting antibody response in 81% of vaccinees ; the geometric mean titer was 1 : 32.
These studies indicate that the cp-45 HPIV-3 vaccine is satisfactorily attenuated, infectious, immunogenic, and phenotypically stable and merits further evaluation in infants and young children.
Mots-clés Pascal : Immunogénicité, Paramyxovirus 3, Paramyxovirus, Paramyxoviridae, Virus, Vaccination, Réponse immune, Toxicité, Immunoprophylaxie, Vaccin, Prévention, Souche atténuée, Evaluation performance, Nourrisson, Homme, Enfant
Mots-clés Pascal anglais : Immunogenicity, Paramyxovirus 3, Paramyxovirus, Paramyxoviridae, Virus, Vaccination, Immune response, Toxicity, Immunoprophylaxis, Vaccine, Prevention, Attenuated strain, Performance evaluation, Infant, Human, Child
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0021938
Code Inist : 002B05C02C. Création : 01/03/1996.